Every material Form 8-K Xeris Biopharma Holdings, Inc. has filed with the SEC since October 14, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Xeris reported third quarter 2026 total revenue of $107.2 million, up 44% from a year earlier, with Recorlev net revenue up 93% to $71.5 million. The company raised its full-year 2026 total revenue guidance to $395 million-$405 million and its 2030 total revenue outlook to more than $1 billion, up from approximately $750 million. Shareholders also face a nine-month net loss of $17.6 million, driven by a one-time non-cash charge of about $30.8 million tied to the 2028 Convertible Notes exchange agreements.
Q3 2026 total revenue was $107.2 million, up 44% from $74.4 million; Recorlev net revenue was $71.5 million, up 93%.
Q3 2026 net income was $11.3 million, or $0.06 per diluted share, compared with $0.6 million a year earlier.
Full-year 2026 total revenue guidance raised to $395 million-$405 million.
Nine-month 2026 net loss was $17.6 million, including a one-time non-cash charge of about $30.8 million in the second quarter.
Xeris Biopharma Holdings appointed Menassie Taddese as a director effective November 2, 2026, increasing the board from eight to nine members and placing him on the Audit Committee. The filing describes his prior roles at Viatris and Pfizer and states the board considers him independent under Nasdaq standards.
Effective November 2, 2026; Taddese is a Class II director with a term expiring at the 2029 annual meeting
Board increased from eight to nine members; Taddese also joins the Audit Committee
Initial equity award with a grant date fair value of approximately $450,000; annual grant of about $300,000 eligible from the 2027 annual meeting
Previously served as President, Emerging Markets at Viatris (November 2020 to December 2022) and held roles at Pfizer from 1997 to 2020
On October 13, 2026, Xeris Biopharma, through subsidiary Xeris Pharmaceuticals, filed patent infringement lawsuits in federal court in New Jersey against several makers of generic dichlorphenamide, the active ingredient in its KEVEYIS product. The suits follow the grant of U.S. Patent No. 12,758,502, and the company seeks an injunction, monetary and enhanced damages, and attorneys' fees. The filing does not include financial figures, so the effect on shareholders will depend on the outcome of the litigation.
Two separate actions filed October 13, 2026, in the U.S. District Court for the District of New Jersey.
Defendants include Torrent Pharma Inc., Torrent Pharmaceuticals Limited, Cycle Pharmaceuticals Limited, Lemed Pharmacy III, LLC, Lemed Specialty Pharmacy Arizona, LLC, Rising Pharma Holdings, Inc., and Rising Pharma Specialties Pvt. Ltd.
The suits concern U.S. Patent No. 12,758,502, related to the KEVEYIS (dichlorphenamide) product.
The company seeks a judgment of infringement, injunctive relief, monetary and enhanced damages, attorneys' fees, and costs.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Xeris Biopharma Holdings, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →